Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Active not recruiting 30Recruiting 25Completed 23Terminated 10Withdrawn 3Suspended 3Unknown 2Not yet recruiting 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1HTLV-I Infections 1

Interventions

Specimen Handling 34Magnetic Resonance Spectroscopy 22Biopsy 20Cyclophosphamide 16Nivolumab 10Paclitaxel 9Cisplatin 9Gemcitabine 8Bevacizumab 8venetoclax 7Vincristine 7Prednisone 7Doxorubicin 7Azacitidine 7pembrolizumab 6Radiotherapy 6Radiosurgery 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Taxes 5Surgical Procedures, Operative 5Rituximab 5Oxaliplatin 5Irinotecan 5Everolimus 5Capecitabine 5fludarabine phosphate 4fludarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Suspended × deltacortene × Clear all
NCT04850495 2026-06-04

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Suspended
38 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03704714 2022-08-15

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Northwestern University

Phase 1/2 Suspended
30 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡